This Article Full Text (PDF) All Versions of this Article: 1533317509334960v1 24/4/293    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Jay Cheol Kwon PubMed PubMed Citation Articles by Jay Cheol Kwon, Social Bookmarking                         What's this?

A Multicenter, Open-Label, 24-Week Follow-Up Study for Efficacy on Cognitive Function of Donepezil in Binswanger-Type Subcortical Vascular Dementia

Department of Neurology, Changwon Fatima Hospital, Changwon, chkwonj{at}gmail.com

Eung Gyu Kim, MD

Department of Neurology, Inje University Pusan Paik Hospital, Busan

Jae Woo Kim, MD

Department of Neurology, Dong-A University Medical Center, Busan

Oh Dae Kwon, MD

Department of Radiology, Daegu Catholic University Medical Center, Daegu

Bong Goo Yoo, MD

Department of Neurology, Kosin University Gospel Hospital, Busan

Hyon Ah Yi, MD

Department of Neurology, Keimyung University Dongsan Medical Center, Daegu

Nack Cheon Choi, MD

Department of Neurology, Gyeongsang National University Hospital, Jinju

Seon Young Ahn, MA

Department of Neurology, Changwon Fatima Hospital, Changwon

Byung Hwa Lee, MA

Department of Neurology, Samsung Medical Center, School of Medicine, Sung Kyun Kwon University Seoul Korea

Myong Jin Kang, MD

Department of Radiology, Dong-A University Medical Center, Busan

Dae Seob Choi, MD

Department of Radiology, , Gyeongsang National University Hospital, Jinju

BKVD Study Group

Objectives: To evaluate the efficacy and tolerability of donepezil in patients with Binswanger type subcortical vascular dementia. Methods: Patients (n = 34, mean age = 71.8 + 7.12) with Binswanger type subcortical vascular dementia from 8 multicenter, according to clinical and neuroradiological working criteria, were selected to receive donepezil 5 mg/day (n = 2) or donepezil 10 mg/day (n = 32, after 5 mg/day) for 24 weeks. Our primary endpoints were change from baseline to weeks 12 and 24 in the Seoul Neuropsychological Screening Battery-Dementia version (SNSB-D) and the Korean version of neuropsychiatric inventory (K-NPI). Results: A total of 24 patients received donepezil completed the study (mean age = 72.0 + 7.5 K-Mini-Mental State Examination [MMSE] = 21.0 + 5.1). After 12 weeks and 24 weeks, patients showed improvements in cognitive function on the SNSB-D compared baseline of 16.29 points at 12 weeks (P < .05) and 12.44 points at 24 weeks (P < .05). Significant improvements were shown in only memory domain, immediate verbal recall and delayed recall tests. Subgroup with better cognitive function (SNSB-D > 100) were more effective in frontal and memory domains than the other subgroup (SNSB-D < 100). Withdrawal rates due to adverse events were very low (4.16%). Conclusions: Donepezil-treated patients with Binswanger type subcortical vascular dementia demonstrated significant improvement in cognition compared with baseline, and donepezil was well tolerated.

Key Words: Binswanger type subcortical vascular dementia • donepezil • cognition

This version was published on August 1, 2009

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 24, No. 4, 293-301 (2009)
DOI: 10.1177/1533317509334960


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?